Sana Biotechnology SANA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sana Biotechnology's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sana Biotechnology's cash & equivalents?
- Sana Biotechnology (SANA) reported cash & equivalents of $83.8M in Q1 2026.
- How has Sana Biotechnology's cash & equivalents changed year-over-year?
- Sana Biotechnology's cash & equivalents decreased by 12.8% year-over-year, from $96.13M to $83.8M.
- What is the long-term trend for Sana Biotechnology's cash & equivalents?
- Over 5 years (2020 to 2025), Sana Biotechnology's cash & equivalents has grown at a -10.5% compound annual growth rate (CAGR), from $124.81M to $71.87M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.